BPC-157 Dosage in Preclinical Research: Protocols, Administration Routes, and Study Design

Overview

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide that has been studied extensively in preclinical animal models. This article summarizes the dosing parameters, administration routes, and study designs reported in published peer-reviewed research. All information is drawn from experimental studies and is provided for research reference only. BPC-157 is not approved for human use by any regulatory authority.

Dose Ranges Used in Published Animal Studies

The majority of published preclinical studies on BPC-157 have employed two primary dose levels: 10 µg/kg and 10 ng/kg body weight. These doses have been used across a wide range of experimental models including musculoskeletal injury, gastrointestinal damage, and neurological studies.

A 2021 review published in Biomedicines (Japjec et al.) described standard BPC-157 regimens in rodent models as 10 µg/kg or 10 ng/kg administered intraperitoneally or per-orally, with the first application immediately post-injury and the last application 24 hours before sacrifice [1]. These dose levels were selected based on earlier dose-response work by Sikiric and colleagues, which established that BPC-157 exhibits biological activity across a broad dose range without apparent dose-limiting toxicity in rodent models [2].

A 2020 preclinical safety evaluation by Xu et al. published in Toxicology Letters tested BPC-157 in mice, rats, rabbits, and dogs. Single-dose studies found no mortality at doses up to 100 mg/kg in rodents, and repeated-dose studies over 13 weeks found reversible effects at high doses with spontaneous recovery after withdrawal [3]. This broad safety margin in animal models has informed the dose ranges used in subsequent mechanistic studies.

Administration Routes

Published studies have employed several administration routes:

Intraperitoneal (i.p.) injection is the most common route in rodent studies, allowing precise dosing and rapid systemic distribution. Most mechanistic studies use i.p. administration.

Oral/per-oral (p.o.) administration has also been studied extensively. BPC-157 demonstrates stability in gastric juice, which is notable given its origin as a peptide isolated from human gastric juice. Oral administration studies have shown comparable effects to i.p. injection in several gastrointestinal models [1, 4].

Local/topical application near the site of injury has been used in wound healing and tendon repair models. Chang et al. (2011) demonstrated that local application at the tendon injury site promoted outgrowth, cell survival, and cell migration [5].

Intramuscular (i.m.) injection has been used in some musculoskeletal studies, particularly those examining muscle and tendon repair.

Study Duration

Study duration in published BPC-157 research varies by model:

- Acute wound healing models: 7–14 days - Tendon and ligament repair models: 2–8 weeks - Gastrointestinal models: 3–14 days - Chronic neurological models: 4–12 weeks

The 2025 systematic review by Vasireddi et al. in Current Reviews in Musculoskeletal Medicine reviewed 47 animal studies and found that the majority used daily administration for 2–4 weeks, with doses ranging from 6 µg/kg to 10 µg/kg [6].

Reconstitution for Research Use

Lyophilized BPC-157 is typically reconstituted in bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) for research use. The standard approach is to add solvent slowly along the vial wall rather than directly onto the lyophilized powder to minimize agitation and potential degradation. Once reconstituted, BPC-157 solutions should be stored at 2–8°C and used within the timeframe specified by the supplier's documentation.

For a 5 mg vial, adding 2.5 mL of bacteriostatic water yields a concentration of 2 mg/mL (2000 µg/mL). Adding 5 mL yields 1 mg/mL (1000 µg/mL). Researchers should calculate volumes based on the specific dose (µg/kg) and subject body weight required by their experimental protocol.

Important Note

All dosing information above refers exclusively to parameters used in published animal research. BPC-157 is sold by Pure Pharm Peptides for research use only and is not intended for human or animal consumption. Researchers should consult their institutional review board (IACUC) and follow applicable regulations for all animal research protocols.

For research use only. Not for human or animal consumption.

References

1. Japjec, M., et al. (2021). Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines, 9(11), 1547.
2. Sikiric, P., et al. (2020). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology, 18(11), 1037–1054.
3. Xu, C., et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Toxicology Letters, 334, 1–8.
4. Sikiric, P., et al. (2011). Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design, 17(16), 1612–1632.
5. Chang, C.H., et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780.
6. Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Current Reviews in Musculoskeletal Medicine, 18(1), 1–10.